Financhill
Sell
46

IRMD Quote, Financials, Valuation and Earnings

Last price:
$57.67
Seasonality move :
7.39%
Day range:
$57.52 - $59.47
52-week range:
$42.34 - $63.29
Dividend yield:
1.11%
P/E ratio:
37.14x
P/S ratio:
9.81x
P/B ratio:
8.13x
Volume:
36.8K
Avg. volume:
63.9K
1-year change:
23.73%
Market cap:
$732M
Revenue:
$73.2M
EPS (TTM):
$1.55

Analysts' Opinion

  • Consensus Rating
    iRadimed has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $71.00, iRadimed has an estimated upside of 23.33% from its current price of $57.57.
  • Price Target Downside
    According to analysts, the lowest downside price target is $70.00 representing 100% downside risk from its current price of $57.57.

Fair Value

  • According to the consensus of 1 analyst, iRadimed has 23.33% upside to fair value with a price target of $71.00 per share.

IRMD vs. S&P 500

  • Over the past 5 trading days, iRadimed has underperformed the S&P 500 by -6.86% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • iRadimed does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • iRadimed has grown year-over-year revenues for 17 quarters straight. In the most recent quarter iRadimed reported revenues of $19.5M.

Earnings Growth

  • iRadimed has grown year-over-year earnings for 2 quarters straight. In the most recent quarter iRadimed reported earnings per share of $0.37.
Enterprise value:
681.7M
EV / Invested capital:
--
Price / LTM sales:
9.81x
EV / EBIT:
30.10x
EV / Revenue:
9.07x
PEG ratio (5yr expected):
3.74x
EV / Free cash flow:
49.48x
Price / Operating cash flow:
53.49x
Enterprise value / EBITDA:
29.09x
Gross Profit (TTM):
$57.8M
Return On Assets:
20.95%
Net Income Margin (TTM):
26.33%
Return On Equity:
23.77%
Return On Invested Capital:
23.77%
Operating Margin:
27.84%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Income Statement
Revenue $56.5M $67.7M $75.2M $17.6M $19.5M
Gross Profit $43.6M $51.8M $57.8M $13.4M $14.8M
Operating Income $16.6M $20.8M $22.6M $4.7M $5.4M
EBITDA $17.7M $21.6M $23.4M $5M $5.6M
Diluted EPS $1.09 $1.41 $1.55 $0.32 $0.37
Period Ending 2021-03-31 2022-03-31 2023-03-31 2024-03-31 2025-03-31
Balance Sheet
Current Assets $65.2M $65.5M $61.3M $71.9M $75.1M
Total Assets $72.2M $72.4M $75.6M $88M $101.7M
Current Liabilities $4.6M $6.2M $6.8M $7.6M $8.5M
Total Liabilities $9.1M $9.8M $11.3M $11.9M $11.7M
Total Equity $63.1M $62.5M $64.3M $76.1M $90.1M
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Cash Flow Statement
Cash Flow Operations $13.3M $12.7M $26M $3.9M $4.3M
Cash From Investing -$7.5M -$1.9M -$12.3M -$478.8K -$3.9M
Cash From Financing -$13.4M -$8.4M -$8.6M -$8M -$2.3M
Free Cash Flow $5.3M $10.8M $13.8M $3.4M $374.8K
IRMD
Sector
Market Cap
$732M
$33.5M
Price % of 52-Week High
90.96%
48.01%
Dividend Yield
1.11%
0%
Shareholder Yield
--
-0.97%
1-Year Price Total Return
23.73%
-33.61%
Beta (5-Year)
0.913
0.621
Dividend yield:
1.11%
Annualized payout:
$0.45
Payout ratio:
39.74%
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $59.88
200-day SMA
Buy
Level $54.49
Bollinger Bands (100)
Buy
Level 51.41 - 58.27
Chaikin Money Flow
Sell
Level -50.8K
20-day SMA
Sell
Level $59.58
Relative Strength Index (RSI14)
Sell
Level 43.95
ADX Line
Sell
Level 17.17
Williams %R
Buy
Level -98.9429
50-day SMA
Buy
Level $56.78
MACD (12, 26)
Buy
Level 13.09
25-day Aroon Oscillator
Buy
Level 36
On Balance Volume
Neutral
Level 71.5K

Financial Scores

Buy
Altman Z-Score (Annual)
Level (39.5547)
Buy
CA Score (Annual)
Level (2.3949)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-6.1885)
Buy
Piotroski F Score (Annual)
Level (8)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (7)

Revenue Forecast

Earnings per Share Forecast

Company Profile

iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.

Stock Forecast FAQ

In the current month, IRMD has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The IRMD average analyst price target in the past 3 months is $71.00.

  • Where Will iRadimed Stock Be In 1 Year?

    According to analysts, the consensus estimate is that iRadimed share price will rise to $71.00 per share over the next 12 months.

  • What Do Analysts Say About iRadimed?

    Analysts are divided on their view about iRadimed share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that iRadimed is a Sell and believe this share price will drop from its current level to $70.00.

  • What Is iRadimed's Price Target?

    The price target for iRadimed over the next 1-year time period is forecast to be $71.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is IRMD A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for iRadimed is a Buy. 1 of 1 analysts rates the stock a Buy at this time.

  • How Can I Buy Shares Of IRMD?

    You can purchase shares of iRadimed via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase iRadimed shares.

  • What Is The iRadimed Share Price Today?

    iRadimed was last trading at $57.67 per share. This represents the most recent stock quote for iRadimed. Yesterday, iRadimed closed at $57.57 per share.

  • How To Buy iRadimed Stock Online?

    In order to purchase iRadimed stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will C3.ai Stock Be in 1 Year?
Where Will C3.ai Stock Be in 1 Year?

C3 .ai (NYSE: AI) has been the poster child for “hype versus execution.”…

What Is the Ceiling for IONQ Stock?
What Is the Ceiling for IONQ Stock?

IonQ (NYSE:IONQ) is a quantum computing startup that, like many…

Can FUBO Stock Double?
Can FUBO Stock Double?

TV streaming service Fubo (NYSE:FUBO) has seen incredible returns so…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
45
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
58
INKT alert for Jul 12

MiNK Therapeutics [INKT] is up 727.94% over the past day.

Buy
51
NEGG alert for Jul 12

Newegg Commerce [NEGG] is up 74.03% over the past day.

Buy
68
ATRO alert for Jul 12

Astronics [ATRO] is up 16.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock